Godrej Agrovet Q4 FY26 Earnings Analysis
Published 17 Aug 2026 | Food Products | Market Cap: ₹11.2K Cr
Price
₹580.5
Market Cap
₹11.2K Cr
P/E Ratio
23.8
Earnings Summary
Astec LifeSciences**: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.
📊 Revenue & Sales Performance
- →**Astec LifeSciences**: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. CDMO revenue share aimed at 52%-53%+.
- →**Animal Nutrition**: Strong volume growth continuing, particularly in cattle feed and newly launched products; focusing on volume-driven revenue growth with double-digit growth expected.
- →**Oil Palm**: Early double-digit volume growth expected, with record area expansion planned; improving oil extraction ratio supports margins.
- →**Crop Care**: Expected strong recovery from Q2 FY27 onwards, aiming for very high double-digit revenue growth post inventory normalization.
- →**Godrej Foods**: Continued double-digit growth in branded products; phased exit from live bird trading with growth in value-added segments like frozen chicken and momos.
- →**Overall FY27 Outlook**: Early double-digit consolidated revenue growth; mid-teens PBT growth targeted, driven mostly by volume expansion.
📈 Profitability & Margins
- →Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.
- →Targeting mid-teens percentage growth in profit before tax (PBT) for FY27.
- →Astec business expected to grow around 15-20%, with CDMO segment growing faster and margins remaining intact.
- →Oil palm business plans double-digit volume growth and increasing value-added product share to 50-55% by FY31 to insulate against price volatility.
- →Animal Nutrition business to continue double-digit volume growth, driven by new product innovations and geographic expansion.
- →Crop Care business expects a strong recovery starting Q2 FY27 with very high double-digit growth.
- →Dividend payout policy remains healthy with 45-47% payout, potential to increase with mid-teens EBITDA growth and capex around INR 300-350 crores.
🏗️ Capital Expenditure Plans
- →Godrej Agrovet plans capex of around INR 350-400 crores per year going forward.
- →Approximately 75%-80% of capex will be growth-oriented.
- →Around 50% of total capex deployment is targeted toward the Oil Palm business.
- →Specific investments include rolling out a specialty fat refinery starting May FY '27, expected to ramp up in the second half of the year.
- →Investment focus on value-added products in Oil Palm to move the portfolio towards 50%-55% value-added products by FY31.
- →Ongoing strategic restructuring and portfolio reviews to unlock shareholder value over a 4-5 year horizon.
- →Emphasis on capacity expansion in animal nutrition, crop care diversification, and new product development.
- →Focus on backward integration in the CDMO business to mitigate supply risks and improve cost competitiveness.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or upcoming equity fundraising in the transcript.
- →Regarding debt or capital expenditure, the company plans capex of around INR 300-400 crores annually in coming years, with 75%-80% towards growth.
- →The company expects to generate free cash flow surplus of around INR 100-125 crores after capex.
- →There is a mention of focusing capital allocation only on high-growth businesses.
- →No direct indication of needing new debt or equity financing for these investments; cash flows seem to support capex plans.
- →Dividend payout policy remains consistent with 45-48% payout, but future policy decisions depend on annual results.
- →The company is maintaining capital discipline and working capital management to keep ROCE strong around 20%.
📋 Order Book & Pipeline
The transcript from the provided pages does not explicitly mention the current or expected order book or pending orders for Godrej Agrovet Limited. However, relevant insights include:
- Astec LifeSciences is witnessing a positive trend with a strong comeback led by CDMO.
- The pipeline funnels for Astec CDMO business are looking pretty good, with some good early leads emerging.
- The company expects growth around 15-20% in Astec’s CDMO business.
- Strategic focus is on increasing value-added portfolio in Crop Care and Oil Palm segments.
- Expansion plans include record-breaking area expansion for Oil Palm next year.
- Emphasis on volume-driven revenue growth across businesses.
- No specific figures on order book or pending orders are provided in the discussed pages.
If you need details on order book or pending orders, it may require further document sections or a formal data request.
Key Metrics
Frequently Asked Questions
What were Godrej Agrovet Q4 FY26 results?
Astec LifeSciences**: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.
What is Godrej Agrovet share price analysis?
Godrej Agrovet currently shows a neutral. The stock trades at a P/E of 23.8 with a market cap of ₹11,166 Cr. Investors should review the full earnings analysis for detailed insights.
Is Godrej Agrovet planning capital expenditure?
Godrej Agrovet plans capex of around INR 350-400 crores per year going forward.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.